TickerTalks
Browse all tickers →
TickerTalks›$MRK
MRMRK

Merck & Co., Inc.

$MRK·$305B·Drug Manufacturers - General·Healthcare
$131.18+2.8%YTD+14.5%1Y+54.9%
Mentions · last 7 days
2026-07-09: 249 posts2026-07-10: 310 posts2026-07-11: 132 posts2026-07-12: 240 posts2026-07-13: 350 posts2026-07-14: 249 posts2026-07-15: 320 posts1,874+6%
Price updated 10m ago·X counts updated 2d ago
MRMRK
$MRKMerck & Co., Inc.
$131.18+2.78%1.9k posts+6%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $MRK, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-07-17

The move is getting stronger, with heavier trading behind it.

The next-gen pipeline is landing — tulisokibart is the specific proof the patent-cliff narrative overshoots.

Merck is the big-pharma incumbent whose Keytruda oncology franchise faces a patent cliff in the late 2020s and whose entire investment case rides on the next-gen pipeline arriving in time. This year the pipeline delivered — tulisokibart hitting its primary endpoint in ulcerative colitis is the specific proof.

Why the setup is aligned:

  • Fundamentals underpin the compounder read: 28% operating margin, 13% return on invested capital, and a 4.7% free cash flow yield — that's the durable cash-generating base that funds R&D through the cliff.
  • The pipeline data landed: tulisokibart meeting its Phase 3 endpoint for clinical remission at 12 weeks is a category-expanding readout — it opens a new immunology revenue lever exactly as Keytruda dependence is what markets have been discounting.
  • The tape is fresh: sitting at 95% of the 52-week range, 7% above the 50-day, up 55% over twelve months — that's the pattern of a name repositioning into fundamentals validation, not a chase.
  • The check is the multiple: 33x TTM P/E is elevated for a pharma name, meaning the pipeline validation has to compound with additional readouts — one Phase 3 win doesn't fully offset the cliff on its own.

Aug 4 earnings is the confirmation. A number confirming Keytruda run-rate plus specific pipeline-readout timelines through 2027 extends the leg; a Keytruda decel or a pipeline slip resets the discount.

Agrees with X sentimentX is bullish on the tulisokibart readout, the Trump-tied US-manufacturing narrative, and the breakout-retest setup, and the fundamentals genuinely back it — a Phase 3 win in immunology is a real category-expander. The check the corpus isn't sizing is that the patent-cliff discount is priced in, so the pipeline has to keep delivering, not just win once.

What to watch: The Aug 4 print — Keytruda run-rate, tulisokibart FDA timeline commentary, and any new Phase 3 readout dates in oncology or immunology. Continued run-rate plus a specific pipeline calendar extends the leg; a Keytruda decel reopens the cliff discount.

On the calendar: 2026-08-04 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment11 posts analyzed · as of 2026-07-15

Merck chatter is bullish. MRK's tulisokibart met the primary endpoint in a late-stage trial, achieving clinical remission in ulcerative colitis patients at 12 weeks - a positive readout for the pipeline. MRK +55% over the past year. Merck received Trump/NATO mention as one of the drugmakers investing $19.2T in US plants and equipment. Community notes MRK breakout + retest with $130 as the next resistance - pop that and 'this pops pretty quick.' Traders collect and reinvest MRK dividends. Community broadly long.

Read the AI verdict + X sentiment for $MRK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes Keytruda cancer immunotherapy, Gardasil HPV vaccine, and animal health products with a strong oncology pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $MRK.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $MRK

Partial — Makes Keytruda cancer immunotherapy, Gardasil HPV vaccine, and animal health products with a strong oncology pipeline; exposure exists but is diluted by diverse end markets and revenue mix.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+17.8%YTD
+47.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
33.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
27.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
17.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
75.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 30, 2026$-1.28$-1.47+12.9%
Q4 2025Feb 3, 2026$2.04$2.01+1.5%
Q3 2025Oct 30, 2025$2.58$2.36+9.3%
Q2 2025Jul 29, 2025$2.13$2.03+4.9%
Next earningsTue, Aug 4·consensus EPS $-0.25

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$16.3B+4.3%81.9%-11.6%$-1.72$2.9B
Q4 FY25$16.3B+4.5%70.5%37.7%$1.20$1.8B
Q3 FY25$17.2B+3.2%75.6%43.4%$2.32$6.8B
Q2 FY25$15.8B-1.9%75.7%40.2%$1.76$2.5B

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$66.8B$66.4B – $67.6B$5.13$5.08 – $5.217
FY27$70.2B$69.3B – $71.7B$9.63$9.41 – $9.818
FY28$74.8B$74.4B – $75.3B$10.67$9.24 – $11.535
FY29$74.4B$73.4B – $75.8B$10.18$10.00 – $10.432
FY30$74.0B$73.1B – $75.4B$9.83$9.66 – $10.072

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.95%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+16.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 2.5B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.205-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 39 other (27 awards · 6 inkinds · 6 exempts) in window

See when $MRK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteMay 288-K — Item 5.07: Shareholder vote
AI summary

Merck & Co., Inc. held its Annual Meeting of Shareholders on May 26, 2026, at which shareholders voted on director elections, executive compensation (say-on-pay), and other proposals as described in the proxy statement. Final voting results for each nominee and proposal are provided in the 8-K. This is a routine annual meeting governance disclosure with no material corporate actions taken.

424B5Prospectus supplement (offering)May 20424B5
AI summary

Merck & Co., Inc. (MRK) priced a $6 billion multi-tranche senior notes offering on May 20, 2026, comprising: $500M Floating Rate Notes due 2028, $1B 4.300% Notes due 2028, $500M 4.650% Notes due 2031, $1B 4.950% Notes due 2033, $1.5B 5.200% Notes due 2036, $500M 5.750% Notes due 2046, and $1B 5.850% Notes due 2056. This is a large investment-grade debt capital markets transaction for Merck; proceeds are likely earmarked for general corporate purposes, which may include funding the company's acquisition strategy or refinancing maturing debt.

424B5Prospectus supplement (offering)May 18424B5
AI summary

Merck and Co., Inc. (MRK) filed a preliminary 424B5 prospectus supplement on May 18, 2026 under Registration No. 333-278066 for a multi-tranche debt offering comprising Floating Rate Notes and multiple fixed-rate note series at various maturities. All specific dollar amounts and interest rates are left blank in this pre-pricing document. This is a debt capital markets transaction (not equity dilution) with proceeds intended for general corporate purposes consistent with Merck's ongoing capital needs.

3/ANew insider — initial holdingsMay 53/A
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3/A (amended) for MRK on 2026-05-05, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2026 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

3New insider — initial holdingsMay 43
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for MRK on 2026-05-04, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2026 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

3New insider — initial holdingsMar 123
+ 19 other (3 11-Ks · 2 13Fs · 2 SC TO-T/As · 2 13Gs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

FDA Approval Adds New Cholesterol Treatment Option in Merck Portfoliobenzinga.com·1d agoFDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kindnypost.com·1d agoNasdaq slides as chip selloff drags Wall Street lowerproactiveinvestors.com·1d agoNasdaq dragged by chip sell-off, Abbott, UnitedHealth lead risersproactiveinvestors.com·1d agoMerck's cholesterol pill gets US FDA approvalreuters.com·1d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$JNJ$PFE$ABBV$GILD$OGN$AMGN
Voices on X · top 6 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport